Irvine-based Aviir Diagnostic Laboratories Inc. said today that it its current investor group has rounded out a total of $30 million in financing initiated roughly 18 months ago.

Aviir offers tests that predict a person’s risk for heart disease.

The company said in a release that the financing was triggered by its “successful achievement of revenue milestones ahead of schedule” although it did not disclose a specific amount.

Aviir’s investor group includes the Merck Global Health Innovation Fund, an arm of Whitehouse Station-based Merck & Co.

The company moved to Irvine in 2011 from the Bay area.